Results 211 to 220 of about 12,421,057 (398)
LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more sourceCumulative Lifetime Burden of Cardiovascular Disease From Early Exposure to Air Pollution
, 2020 Juyong Brian Kim, Mary Prunicki, François Haddad, Christopher Dant, Vanitha Sampath, Rushali Patel, Eric Smith, Cezmi A. Akdiş, John R. Balmes, M Snyder, Joseph C. Wu, Kari C. Nadeau +11 moreopenalex +1 more sourceGlobal, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
The Lancet Haematology, 2023 A. Thomson, T. A. McHugh, A. Oron, Corey Teply, Nikhil Lonberg, Victor Vilchis Tella, Lauren B. Wilner, Kia C Fuller, Hailey Hagins, R. Aboagye, Melka Biratu Aboye, Eman Abu-Gharbieh, A. Abu-Zaid, Isaac Yeboah Addo, B. Ahinkorah, Aaminah Ahmad, S. A. AlRyalat, Hubert Amu, A. Aravkin, Judie Arulappan, Maha Moh’d Wahbi Atout, A. Badiye, S. Bagherieh, Maciej Banach, Morteza Banakar, Mainak Bardhan, Amadou Barrow, Deriba A. Bedane, I. Benseñor, A. Bhagavathula, Pankaj Bhardwaj, Prarthna V. Bhardwaj, A. N. Bhat, Z. Bhutta, M. Bilalaga, Jessica Bishai, Saeid Bitaraf, A. Boloor, M. H. Butt, Vijay Kumar Chattu, D. Chu, O. Dadras, X. Dai, B. Danaei, Anh Kim Dang, Fitsum Wolde Demisse, M. Dhimal, Daniel Diaz, S. Djalalinia, Deepa Dongarwar, Muhammed Elhadi, Mohamed A. Elmonem, C. Esezobor, Farshid Etaee, Oghenowede Eyawo, A. Fagbamigbe, A. Fatehizadeh, Lisa M. Force, W. Gardner, Kazem Ghaffari, P. Gill, Mahaveer Golechha, Pouya Goleij, Vikrant Gupta, H. Hasani, Treska S. Hassan, Mohammed Bheser Hassen, S. E. Ibitoye, A. Ikiroma, C. C. Iwu, P. James, S. Jayaram, R. Jebai, Ravi Prakash Jha, N. Joseph, Farnaz Kalantar, Himal Kandel, I. Karaye, Woldeteklehaymanot Kassahun, Imteyaz A Khan, S. Khanmohammadi, A. Kisa, Farzad Kompani, K. Krishan, I. Landires, Stephen S. Lim, P. Mahajan, Prof. Dr. Soleiman Mahjoub, A. Majeed, B. Marasini, Haftu Asmerom Meresa, T. Meštrović, Sonica Minhas, A. Misganaw, A. Mokdad, L. Monasta, Ghulam Mustafa, T. Nair, S. Narasimha Swamy, H. Nassereldine, Z. Natto, Muhammad Naveed, B. Nayak, J. Noubiap, Taylor Noyes, C. Nri-Ezedi, V. Nwatah, CHIMEZIE IGWEGBE NZOPUTAM, O. Nzoputam, Osaretin Christabel Okonji, A. Onikan, M. Owolabi, Jay Patel, Siddhartha Pati, Shrikant Pawar, Ionela-Roxana Petcu, F. Piel, Ibrahim Qattea, Mehran Rahimi, Mosiur Rahman, S. Rawaf, E. Redwan, N. Rezaei, B. Saddik, U. Saeed, Fatemeh Saheb Sharif‐Askari, A. Samy, Austin E. Schumacher, Elaheh Shaker, Adithi S. Shetty, M. Sibhat, Jasvinder A. Singh, Muhammad Suleman, Dev Ram Sunuwar, M. Szeto, J. L. Tamuzi, Nathan Y. Tat, Birhan Tsegaw Taye, M. Temsah, Muhammad Umair, Sahel Valadan Tahbaz, Cong Wang, N. Wickramasinghe, A. Yi̇ği̇t, Vahit Yi̇ği̇t, Ismaeel Yunusa, B. Zaman, M. Zangiabadian, Peng Zheng, Simon Iain Hay, M. Naghavi, C. Murray, N. Kassebaum +152 moresemanticscholar +1 more sourceA subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli +3 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more source
